Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Helaba in connection with financing of an acquisition in real estate
Mandate

Vinge has advised Helaba in connection with financing of an acquisition in real estate

June 16, 2017 Banking and Finance

TRIUVA Kapitalverwaltungsgesellschaft mbH, Germany’s leading real estate fund manager, has acquired from Slussgården the city property Lammet 17, located right next to Drottninggatan and Kungsgatan.

The property has 6,700 square meters of office and retail space and Fastighetsvärlden estimates that the price amounts to a bit over 450 million SEK. Catella and Foyen have been advisors to Slussgården and JLL, Roschier, King & Spalding, WSP and Rödl & Partner have been advisors to Triuva. Vinge has advised Landesbank Hessen-Thüringen Girozentrale (Helaba) in connection with the financing of the acquisition.

Vinge’s team consisted of Mikael Ståhl, Helena Håkansson, André Isacson and Ludvig Wettergren.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024